X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (186) 186
Publication (8) 8
Patent (5) 5
Newspaper Article (4) 4
Trade Publication Article (4) 4
Book / eBook (3) 3
Magazine Article (3) 3
Book Chapter (2) 2
Dissertation (2) 2
Book Review (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (74) 74
cardiac & cardiovascular systems (59) 59
male (57) 57
female (54) 54
aged (52) 52
index medicus (51) 51
middle aged (49) 49
cardiovascular (42) 42
cardiac patients (34) 34
percutaneous coronary intervention (34) 34
internal medicine (33) 33
clopidogrel (32) 32
treatment outcome (31) 31
care and treatment (29) 29
heart attacks (29) 29
acute coronary syndromes (28) 28
transluminal angioplasty (27) 27
heart attack (24) 24
coronary heart disease (23) 23
risk factors (22) 22
myocardial infarction (20) 20
platelet aggregation inhibitors - adverse effects (20) 20
prasugrel (20) 20
ticlopidine - analogs & derivatives (19) 19
abridged index medicus (18) 18
angioplasty (18) 18
cardiology and cardiovascular medicine (18) 18
hemorrhage - chemically induced (18) 18
mortality (18) 18
platelet aggregation inhibitors - administration & dosage (18) 18
platelet aggregation inhibitors - therapeutic use (17) 17
prospective studies (17) 17
time factors (17) 17
acute coronary syndrome (16) 16
intervention (16) 16
peripheral vascular disease (16) 16
drug therapy (15) 15
myocardial infarction - therapy (15) 15
patient outcomes (15) 15
adult (14) 14
double-blind method (14) 14
therapy (14) 14
abciximab (13) 13
outcomes (13) 13
ticlopidine - administration & dosage (13) 13
usage (13) 13
acute coronary syndrome - therapy (12) 12
analysis (12) 12
management (12) 12
antibodies, monoclonal - adverse effects (11) 11
association task-force (11) 11
immunoglobulin fab fragments - adverse effects (11) 11
medical colleges (11) 11
patients (11) 11
acute myocardial-infarction (10) 10
antibodies, monoclonal - therapeutic use (10) 10
hematology (10) 10
immunoglobulin fab fragments - therapeutic use (10) 10
pharmacology & pharmacy (10) 10
prasugrel hydrochloride (10) 10
purinergic p2y receptor antagonists - administration & dosage (10) 10
blood platelets - drug effects (9) 9
cardiology (9) 9
follow-up studies (9) 9
medical research (9) 9
percutaneous coronary intervention - adverse effects (9) 9
platelet function tests (9) 9
prasugrel hydrochloride - adverse effects (9) 9
prasugrel hydrochloride - therapeutic use (9) 9
risk (9) 9
stents (9) 9
thrombosis (9) 9
ticlopidine - adverse effects (9) 9
ticlopidine - therapeutic use (9) 9
united states (9) 9
aspirin (8) 8
bleeding (8) 8
clinical outcomes (8) 8
clinical trials (8) 8
diabetes (8) 8
dose-response relationship, drug (8) 8
health risk assessment (8) 8
infarction (8) 8
inhibition (8) 8
piperazines - administration & dosage (8) 8
platelet aggregation - drug effects (8) 8
stroke (8) 8
thiophenes - administration & dosage (8) 8
trial (8) 8
angioplasty, balloon, coronary (7) 7
angioplasty, balloon, coronary - adverse effects (7) 7
anticoagulants - therapeutic use (7) 7
blood platelets (7) 7
cerebral infarction (7) 7
comparative analysis (7) 7
events (7) 7
hemorrhage - epidemiology (7) 7
hospitalization (7) 7
longitudinal studies (7) 7
medicine, experimental (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2008, Volume 358, Issue 21, pp. 2205 - 2217
Immediate percutaneous coronary intervention (PCI) is the treatment of choice for acute ST-segment elevation myocardial infarction. In this study, PCI that was... 
IMMEDIATE ANGIOPLASTY | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | TO-BALLOON TIME | 30-DAY MORTALITY | INTRAVENOUS THROMBOLYTIC THERAPY | RISK PATIENTS | REPERFUSION THERAPY | SYMPTOM-ONSET | PRIMARY ANGIOPLASTY | FIBRINOLYTIC THERAPY | Myocardial Infarction - mortality | Myocardial Infarction - classification | Humans | Immunoglobulin Fab Fragments - adverse effects | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Immunoglobulin Fab Fragments - therapeutic use | Recombinant Proteins - adverse effects | Tissue Plasminogen Activator - adverse effects | Angioplasty, Balloon, Coronary | Fibrinolytic Agents - adverse effects | Myocardial Infarction - therapy | Time Factors | Electrocardiography | Female | Cerebral Infarction - chemically induced | Double-Blind Method | Kaplan-Meier Estimate | Tissue Plasminogen Activator - administration & dosage | Treatment Outcome | Combined Modality Therapy | Recombinant Proteins - administration & dosage | Myocardial Infarction - complications | Aged | Fibrinolytic Agents - administration & dosage | Hemorrhage - chemically induced | Care and treatment | Abciximab | Coronary artery bypass | Comparative analysis | Health aspects | Heart attack | Angioplasty | Heart attacks | Intubation | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2019, Volume 73, Issue 9, pp. 2911 - 2911
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 11, pp. 24 - 24
  Conclusions: Among post-MI patients with a recurrent ischemic event, intensification of antiplatelet therapy was rare, even among patients with stent... 
Cardiovascular | Internal Medicine | Ischemia | Care and treatment | Cardiac patients | Thrombosis
Journal Article
Journal Article
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, ISSN 1522-1946, 10/2016, Volume 88, Issue 4, pp. 535 - 544
Journal Article
American Heart Journal, ISSN 0002-8703, 01/2017, Volume 183, pp. 62 - 68
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 11, pp. 1348 - 1348
  After propensity matching planned GPI use was associated with increased BARC 2+ bleeding risk but no significant difference in MACE, regardless of P2Y12... 
Cardiovascular | Internal Medicine | Care and treatment | Cardiac patients | Heart attack | Health risk assessment | Glycoproteins
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2015, Volume 66, Issue 15, pp. B63 - B64
  MACE was the composite of all-cause death, coronary revascularization, or rehospitalization for MI, unstable angina (UA), TIA/stroke, or CHF. NACE 2,254... 
Cardiovascular | Internal Medicine | Transluminal angioplasty | Comparative analysis | Coronary heart disease | Cardiac patients | Patient outcomes | Heart attacks | Acute coronary syndromes | Angina pectoris | Clinical outcomes
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2016, Volume 67, Issue 1, pp. 59 - 65
Abstract Background Prolonged dual antiplatelet therapy (DAPT) is recommended after an acute myocardial infarction (AMI) to reduce ischemic events but is... 
Cardiovascular | Internal Medicine | percutaneous coronary intervention | bleeding | antiplatelet therapy | quality of life | Sects | Medical colleges | Anticoagulants | Hospitalization | Heart attacks | Cardiology
Journal Article
American Heart Journal, ISSN 0002-8703, 06/2017, Volume 188, pp. 73 - 81
We sought to determine the frequency of use and association between prasugrel and outcomes in acute coronary syndrome patients undergoing percutaneous coronary... 
CLAIMS DATA | TRIAL | CARDIAC & CARDIOVASCULAR SYSTEMS | INHIBITION | MANAGEMENT | RISK | THROMBOLYSIS | PATTERNS | TRITON-TIMI 38 | CYP2C19 | ELEVATION MYOCARDIAL-INFARCTION | Purinergic P2Y Receptor Antagonists - administration & dosage | Survival Rate - trends | Follow-Up Studies | Humans | Middle Aged | Acute Coronary Syndrome - mortality | Male | Treatment Outcome | Ticlopidine - analogs & derivatives | Dose-Response Relationship, Drug | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - administration & dosage | Acute Coronary Syndrome - therapy | Cause of Death - trends | Female | Aged | Retrospective Studies | Prasugrel Hydrochloride - administration & dosage | Percutaneous Coronary Intervention | Preoperative Period | Transluminal angioplasty | Usage | Care and treatment | Coronary heart disease | Cardiac patients | Patient outcomes | Blood transfusion | Myocardial infarction | Performance evaluation | Intervention | Transfusion | Heart attacks | Angioplasty | Clinical trials | Prometheus | Bleeding | Blood | Risk factors | Data bases | Training | Ischemia | Risk assessment | Attenuation | Drug therapy | Age | Cerebral infarction | Adenosine | Stroke | Adjustment | Mortality | Regression | Risk analysis | Patients | Studies | Clopidogrel | Death | Infarction | Acute coronary syndromes
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2015, Volume 66, Issue 15, pp. B85 - B85
  Methods PROMETHEUS was a retrospective multicenter observational study comparing clopidogrel and prasugrel use in patients undergoing PCI for acute coronary... 
Cardiovascular | Internal Medicine | Body mass index | Heart attacks | Angina pectoris | Acute coronary syndromes
Journal Article
Progress in Cardiovascular Diseases, ISSN 0033-0620, 01/2018, Volume 60, Issue 4-5, pp. 531 - 536
Atrial fibrillation (AF) is a common arrhythmia that increases in prevalence with advancing age and in patients with coronary artery disease,... 
Observation study | Non-vitamin K oral anticoagulant | Atrial fibrillation | Percutaneous coronary intervention | Review | Dual antiplatelet therapy | Triple antithrombotic therapy
Journal Article
Journal Article
Catheterization and Cardiovascular Interventions, ISSN 1522-1946, 03/2017, Volume 89, Issue 4, pp. 629 - 637
Journal Article